Attorney General sues Seattle Public Schools for alleged illegal treatment of pregnant employees
According to the suit, SPS 'routinely failed to provide legally required accommodations to pregnant and nursing employees such as flexible restroom breaks, modified work schedules, and the ability to sit more frequently.'
KIRO 7 has reached out to the school district for comment and has yet to hear back.
The suit alleges that one employee, while eight months pregnant, was unable to sit her entire workday.
'The state's investigation revealed that Seattle Public Schools did not have a district-level policy for how to handle pregnancy accommodation requests from employees. The district also failed to provide reasonable break time to express milk, or clean and private locations for nursing employees to pump. Employees were walked in on while expressing milk, endured painful clogged ducts, and experienced infections like mastitis. One employee felt 'they had no choice but to take leave to continue breastfeeding,' according to the complaint.
The suit also alleges the school district violated state law by retaliating against employees who sought reasonable accommodations.
The practices detailed in the suit, dating back to at least 2021, allegedly violate the state Healthy Starts Act and the Washington Law Against Discrimination, according to the AG's office.
The lawsuit, filed in King County Superior Court, 'seeks to halt Seattle Public Schools from engaging in its discriminatory practices and award restitution to each impacted employee,' the suit reads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
07-08-2025
- Business Wire
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in autoimmune diseases On track to report preliminary clinical data for ADI-001 in 2H/2025 Enrollment now open for patients with idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) Advancing development of ADI-212, an optimized next-generation gene-edited and armored clinical candidate designed to enhance potency in solid tumors and to deliver multiple anti-tumor mechanisms of action to the tumor microenvironment REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2025. 'We continue to make meaningful progress in our ADI-001 autoimmune Phase 1 clinical program. Site activation is progressing well with more than 20 sites currently open for enrollment in multiple territories and additional sites on track to open in the next few months. We see increased interest by investigators and patients in ADI-001 as a well-tolerated, off the shelf, one-time potential therapy for patients with autoimmune diseases. Enrollment is gathering momentum and we remain on track to share preliminary Phase 1 data for the program in the second half of 2025, with at least 6 patients with at least 3 months' follow-up, which we believe will further validate the differentiated potential of our gamma delta T cell platform,' said Chen Schor, President and Chief Executive Officer of Adicet Bio. 'In addition, we have recently conducted a strategic review of our pipeline to focus our resources on programs with the greatest potential for long-term clinical and commercial value. As such, we are prioritizing the preclinical development of ADI-212, a gene-edited and armored clinical candidate designed to enhance potency in solid tumors and to deliver multiple anti-tumor mechanisms of action to the tumor microenvironment. Our commitment to executing with focus, operational excellence, and discipline position us to deliver differentiated gamma delta 1 CAR T therapies with the best potential to address medical need for patients.' Second Quarter 2025 and Recent Operational Highlights: Autoimmune diseases First SSc patient dosed in ongoing Phase 1 clinical trial in autoimmune diseases. In July 2025, Adicet announced that the first SSc patient was dosed in the second cohort of the Phase 1 clinical trial evaluating ADI-001 in autoimmune disease, in addition to ongoing enrollment in LN and SLE. The Company recently opened enrollment in the Phase 1 trial to include patients with IIM, SPS and AAV. Adicet remains on track to share preliminary clinical data from the Phase 1 trial in the second half of 2025. Solid tumor indications Prioritizing ADI-212 development for prostate cancer. Adicet is advancing ADI-212, an optimized next-generation gene-edited and armored clinical candidate designed to enhance potency in solid tumors and to deliver multiple anti-tumor mechanisms of action to the tumor microenvironment. ADI-212, which targets prostate specific membrane antigen (PSMA), has shown enhanced activity in preclinical studies, suggesting the potential for improved potency and tumor-cell killing capacity compared to previous generation alpha-beta and gamma-delta CAR T programs in oncology. The Company expects to submit a regulatory filing for ADI-212 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the first quarter of 2026. Subject to regulatory clearance to proceed with a clinical trial, the Company expects to report initial clinical data from this program in the second half of 2026. Corporate updates Recently announced pipeline prioritization with workforce and cost reduction initiatives. In July 2025, the Company announced a strategic prioritization of its pipeline intended to optimize the development of assets with the greatest potential for clinical and commercial success. In connection with this, the Company has made the decision to discontinue the development of ADI-270 for patients with metastatic/advanced clear renal cell carcinoma (ccRCC) and close enrollment in the ADI-270 Phase 1 clinical trial. Adicet also reduced its workforce by approximately 30% in connection with its strategic pipeline prioritization. The workforce reduction and other expense reductions related to the strategic pipeline prioritization are expected to extend the Company's cash runway into the fourth quarter of 2026. Financial Results for Second Quarter 2025: Research and Development (R&D) Expenses: R&D expenses were $28.4 million for the three months ended June 30, 2025, compared to $25.9 million during the same period in 2024. The increase in R&D expenses was due to a $1.4 million increase in expenses related to contract development and manufacturing organizations and contracted R&D services, a $1.6 million increase in facility-related expenses, and a $0.2 million increase in lab supplies and materials. This increase was partially offset by a $0.7 million decrease in payroll and personnel expenses primarily related to a decrease in stock-based compensation expense. General and Administrative (G&A) Expenses: G&A expenses were $4.0 million for the three months ended June 30, 2025, compared to $6.9 million during the same period in 2024. The decrease in G&A expenses was due to a $1.8 million decrease in payroll and personnel expenses primarily related to a decrease in stock-based compensation expense and a $1.1 million decrease in facility-related expenses. Net Loss: Net loss for the three months ended June 30, 2025 was $31.2 million, or a net loss of $0.34 per basic and diluted share, including non-cash stock-based compensation expense of $2.9 million, as compared to a net loss of $29.9 million, or a net loss of $0.33 per basic and diluted share, including non-cash stock-based compensation expense of $6.0 million during the same period in 2024. Cash Position: Cash, cash equivalents and short-term investments were $125.0 million as of June 30, 2025, compared to $176.3 million as of December 31, 2024. The Company expects that current cash, cash equivalents and short-term investments as of June 30, 2025, will be sufficient to fund its operating expenses into the fourth quarter of 2026. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at Forward-Looking Statements This press release contains 'forward-looking statements' of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: clinical development of Adicet's product candidates, including future plans or expectations for ADI-001 in autoimmune diseases and the potential safety, tolerability and efficacy for the treatment of autoimmune diseases and cancer; timing and success of the Phase 1 clinical trial of ADI-001 in LN, SLE, SSc, AAV, IIM and SPS, including timing and expectations for enrollment and future data releases; expectations regarding the preclinical and clinical development of ADI-212, including the timing of regulatory filings and future data releases; expectations regarding the potential potency of ADI-212, as compared to previous generation alpha-beta and gamma-delta CAR T programs in oncology; expectations regarding the pipeline prioritization and workforce reduction, including as it relates to the estimated reduction in expenses and the development of assets with the greatest potential for clinical and commercial success; and expectations regarding Adicet's uses of capital, expenses and financial results, including the expected extension of the cash runway into the fourth quarter of 2026. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet's business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet's ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section titled 'Risk Factors' in Adicet's most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Adicet's other filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law. ADICET BIO, INC. Consolidated Balance Sheets Information (in thousands) (Unaudited) June 30, 2025 December 31, 2024 Cash and cash equivalents, and short term investments in treasury securities $ 124,963 $ 176,303 Working Capital 110,661 160,744 Total assets 162,972 220,219 Accumulated deficit (557,325 ) (497,894 ) Total stockholders' equity 133,372 186,609 Expand Contacts Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge abowdidge@ Penelope Belnap Precision AQ 212-362-1200 Adicet Bio, Inc. NASDAQ:ACET Release Versions English Contacts Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge abowdidge@ Penelope Belnap Precision AQ 212-362-1200 More News From Adicet Bio, Inc. Get RSS Feed Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York. Details of the event are as follows: Date: Wednesday, June 4, 2025 Time: 4:20... Back to Newsroom
Yahoo
12-06-2025
- Yahoo
Christian-owned spa loses court battle over banning trans women in WA
This story was originally published on A federal appeals court ruled in favor of Washington after the state told a Christian-owned traditional Korean spa that barring transgender women from its services violates the state's anti-discrimination law. Olympus Spa is a women-only spa located in Lynnwood and Tacoma. In 2023, the owners of Olympus Spa filed a lawsuit against Washington, claiming their First Amendment rights would be violated by allowing trans women to enter. Olympus Spa's policy restricts entry to 'biological women,' excluding men and preoperative transgender women (those who have not had gender-confirmation surgery). The Washington State Human Rights Commission claimed the spa's barring of transgender women was a violation of Washington's Law Against Discrimination. Two years later, a federal appeals court agreed, stating that this ruling does not violate the spa's rights to the freedom of religion, speech, and association. 'The spa's religious expression was only incidentally burdened,' Judge M. Margaret McKeown wrote in the majority opinion, claiming that the limits of the spa owner's free speech were essential to eliminate discriminatory conduct. This conflict between the state and Olympus Spa started in 2020 when the spa turned away a transgender woman, asking if she could receive the spa's services. The spa told the customer they excluded transgender women who had not undergone gender confirmation surgery. The Washington Law Against Discrimination was amended in 2006 to prohibit public facilities from discriminating on the basis of sexual orientation. The Washington definition of sexual orientation includes gender expression and identity.
Yahoo
03-06-2025
- Yahoo
Springfield schools raises 67,000 meals in Ozarks Food Harvest competition
SPRINGFIELD, Mo. — Springfield Public Schools (SPS) has raised over 67,000 meals during the 2025 Food Fight this year. According to an Ozarks Food Harvest press release, SPS students and various organizations participated in the 14th annual Food Fight competition to support Ozarks Food Harvest in March and April. The contest involved 38 schools and four administrative offices collecting food and funds over a two-week period to support The Food Bank, the release says. 'The partnership with Ozarks Food Harvest has not only helped alleviate immediate needs but also fostered a nurturing environment where students and their families feel supported and valued,' Jessica Blake, coordinator of community relations for SPS, said in a press release. 'We are grateful for our ongoing partnership, the support they give to us and the families we serve.' Food donated from the contest will be distributed through Ozark Food Harvest's 28-county service area. Funds will be used for the Weekend Backpack Program that gives meals to over 49 children. This year's winners included Study High School, Westport K-8, Wilson's Creek Intermediate, Boyd Elementary, Cowden Elementary, Mark Twain Elementary, McBride Elementary, York Elementary and Mallory ECC. 'We're so proud to work with Springfield Public Schools, presenting sponsor Rapid Roberts and other partnering organizations across Springfield for Food Fight,' Bart Brown, president at Ozarks Food Harvest, said in the release. 'These meals will go a long way toward helping the 1 in 5 children and 1 in 6 adults who face hunger here in the Ozarks.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
